Rare

罕见
  • 文章类型: Case Reports
    淋巴浆细胞性淋巴瘤(LPL)是一种恶性增生的小淋巴细胞,淋巴细胞样细胞和影响骨髓的浆细胞,淋巴结和脾脏。其发病率为1/100,000,占所有淋巴瘤的8%。总共约5%的LPL患者可能分泌IgG的非IgM,IgA,κ或λ型或非分泌型。在本研究中,据报道,1例62岁女性患者被诊断为非IgM型LPL,其κ轻链单克隆副蛋白产生和血清免疫球蛋白水平正常.使用骨髓样品通过分子遗传分析检测MYD88L265P突变。患者接受了苯达莫司汀-利妥昔单抗联合治疗,后来,将依鲁替尼(布鲁顿激酶抑制剂)添加到治疗方案中。作者的目的是描述在大学医院“圣伊万·里尔斯基”研究和治愈的罕见类型的LPL病例,以及显示用于其诊断的方法及其适用性。解决了诊断此类罕见的LPL病例的困难,这些病例与明显的浆细胞分化和类似浆细胞瘤的IgA副蛋白分泌有关。从另一边,有利于LPL诊断的特征是浆细胞的免疫表型,以及MYD88L265P突变的存在。最后,报告了这种类型淋巴瘤的管理和治疗方法,强调布鲁顿TK抑制剂(依鲁替尼)治疗的有利效果。
    Lymphoplasmacytic lymphoma (LPL) is a malignant proliferation of small lymphocytes, lymphoplasmocytoid cells and plasmocytes affecting the bone marrow, lymph nodes and spleen. Its incidence is 1/100,000 and represents 8% of all lymphomas. A total of ~5% of patients with LPL may secrete non-IgM of IgG, IgA, kappa or lambda type or be non-secretory. In the present study, a case of a 62-year-old female patient who was diagnosed with non-IgM LPL with kappa light chain monoclonal paraprotein production and normal serum immunoglobulin levels was reported. The MYD88 L265P mutation was detected by molecular genetic analysis using a sample of the bone marrow. The patient underwent initial treatment with a combination of Bendamustine-Rituximab, and later on, Ibrutinib (a Bruton kinase inhibitor) was added to the treatment protocol. The authors\' aim was to describe a case of a rare type of LPL studied and cured at the University Hospital \'St. Ivan Rilski\', as well as to show the methods used for its diagnosis and their applicability. The difficulty in diagnosing such rare cases of LPL which are associated with marked plasmacytic differentiation and IgA paraprotein secretion resembling plasma cell neoplasia was addressed. From the other side, the characteristic features in favor of LPL diagnosis are the immunophenotype profile of plasmocytes, as well as the presence of MYD88 L265P mutation. Finally, the methods of management and treatment of this type of lymphoma were reported, highlighting the favorable effect of the treatment with Bruton TK inhibitor (Ibrutinib).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    神经鞘瘤是一种良性神经鞘瘤,由周围神经鞘的雪旺细胞引起,病因不确定。它是包封良好且生长缓慢的肿瘤。大约25-48%的病例见于头颈部。口腔神经鞘瘤的发病率约为1%。舌基神经鞘瘤是一种罕见的实体。它可以影响所有年龄组,通常表现为无痛肿块。然而,当它长大超过3厘米时,它可能会产生吞咽困难,疼痛,或不适和声音质量的变化。因此,神经鞘瘤应被视为舌外生性肿块的鉴别诊断之一。我们报告了一例罕见的舌根神经鞘瘤,患有肿块的26岁男性,以及对过去64年发表的文献的回顾。
    Schwannoma is a benign nerve sheath tumor that arises from Schwann cells of the peripheral nerve sheath with uncertain etiology. It is well-encapsulated and a slow-growing tumor. Approximately 25-48% of cases are seen in the head and neck region. Schwannoma of the oral cavity has an approximate incidence of 1%. Tongue base Schwannoma is a rare entity. It can affect all age groups and typically presents as a painless lump. However, when it grows larger than 3 cm, it may produce dysphagia, pain, or discomfort and change in the quality of voice. Hence, Schwannoma should be considered as one of the differential diagnoses of exophytic mass of the tongue. We report a rare case of Schwannoma of the base of the tongue in a 26-year-old male who presented with a complaint of lump, along with a review of the literature published in the last 64 years.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    植物冷冻库在现代科学和育种中起着重要作用。它们有助于恢复丢失的物种,植物新品种的出现,并帮助保护和探索植物世界的多样性。IPPRASCryobank系列不断补充新样品,while,同时,存储的样品正在被监测。为了测试种子发芽,葱属和verratum物种的种子被解冻。稀有葱属物种种子,例如A.Nutans,A.学校规范,紫草在液氮中储存了17年、19年和30年,分别。长期冷冻保存可使坚果的发芽率从96.55降至50.00%,对于A.schoenoprasum从72.00到62.75%,维氏A从90.00到83.05%。一种稀有药用物种的种子,Veratumlobelianum,在液氮中保存了18年;在此存储期间,种子发芽率已从75.00%显着降低到14.81%。还收集黑曲霉种子并在液氮中冷冻3天。短期冷冻保存不会导致发芽率的统计学显着变化(从79.71到82.69%)。濒危观赏物种的种子,钙蓝,收集并冷冻3天。冷冻保存后,种子被种植在三种不同的培养基上,如下:½MS,MS含10%椰奶,BM1在½MS培养基上,24.98%的种子形成原球茎,在含有10%椰奶的MS培养基上,这个数字是10.02%,在BM1培养基上,是15.02%,分别;然而,2.5个月后,所有的原球虫都死了.因此,现有的黄云种子冷冻保存方案似乎需要进一步改进.大小,体重,并测量了六个先前冷冻保存的针茅属和三个葱属的自由水含量(WC)。对于所有研究的葱属和针茅物种,我们发现种子大小之间没有相关性,WC,和低温耐受性。我们还发现生命形式之间没有相关性,这反映了物种的需水量,和低温耐受性。
    Plant cryobanks play a significant role in modern science and breeding. They contribute to the recovery of lost species, the emergence of new plant varieties, and help preserve and explore the diversity of the plant world. The IPPRAS Cryobank collection is constantly supplemented with new samples, while, at the same time, the stored samples are being monitored. In order to test seed germination, seeds of Allium and Veratrum species were thawed. Rare Allium species seeds, such as A. nutans, A. schoenoprasum, and A. victorialis were stored in liquid nitrogen for 17, 19, and 30 years, respectively. Long-term cryopreservation decreased germination rates for A. nutans from 96.55 to 50.00%, for A. schoenoprasum from 72.00 to 62.75%, and for A. victorialis from 90.00 to 83.05%. Seeds of a rare medicinal species, Veratrum lobelianum, were stored in liquid nitrogen for 18 years; the seed germination rate during this storage period has been significantly decreased from 75.00 to 14.81%. V. nigrum seeds were also collected and frozen in liquid nitrogen for 3 days. Short-term cryopreservation did not result in a statistically significant change in germination rates (from 79.71 to 82.69%). The seeds of an endangered ornamental species, Cypripedium calceolus, were collected and kept frozen for 3 days. After cryopreservation, the seeds were planted on three different media, as follows: ½ MS, MS with 10% coconut milk, and BM1. On ½ MS medium, 24.98% seeds formed protocorms, while on MS medium with 10% coconut milk, this number was 10.02%, and on BM1 medium, it was 15.02%, respectively; however, after 2.5 months, all of the protocorms died. Thus, it appears that the existing protocol for seed cryopreservation of C. calceolus needs further improvement. The size, weight, and free water content (WC) of six previously cryopreserved Stipa species and three Allium species were measured. For all the Allium and Stipa species studied, we found no correlation between seed size, WC, and cryotolerance. We also found no correlation between the life form, which reflects the water requirement of the species, and cryotolerance.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:应使用真实世界的患者数据对人工智能(AI)症状检查器模型进行训练,以提高其诊断准确性。鉴于目前在临床实践中使用基于AI的症状检查程序,随着时间的推移,他们的表现应该会有所改善。然而,对这些症状检查程序诊断准确性的纵向评估是有限的.
    目的:本研究旨在评估真实世界中使用的基于AI的症状检查程序创建的鉴别诊断列表准确性的纵向变化。
    方法:这是一个单中心,回顾性,观察性研究。在2019年5月1日至2022年4月30日期间,在没有预约的情况下访问了门诊诊所,并且在索引访问后30天内被送往日本社区医院的患者被认为是合格的。我们只包括在索引访视时接受基于AI症状检查的患者,最终在随访期间确诊。最终诊断分为常见或不常见,所有病例均分为典型或非典型.主要结果指标是基于AI的症状检查器创建的鉴别诊断列表的准确性,在症状检查程序创建的10项鉴别诊断列表中定义为最终诊断。为了评估症状检查者3年内诊断准确性的变化,我们使用卡方检验比较了3个时期的主要结果:2019年5月1日至2020年4月30日(第一年);2020年5月1日至2021年4月30日(第二年);2021年5月1日至2022年4月30日(第三年).
    结果:共纳入381例患者。常见疾病包括257例(67.5%),在298例(78.2%)病例中观察到典型表现。总的来说,基于AI的症状检查器创建的鉴别诊断列表的准确性为172(45.1%),在3年内没有差异(第一年:97/219,44.3%;第二年:32/72,44.4%;第三年:43/90,47.7%;P=.85)。症状检查器创建的鉴别诊断列表的准确性在那些患有罕见疾病(30/124,24.2%)和非典型表现(12/83,14.5%)的患者中很低。在多元逻辑回归模型中,常见疾病(P<.001;比值比4.13,95%CI2.50-6.98)和典型表现(P<.001;比值比6.92,95%CI3.62-14.2)与症状检查程序创建的鉴别诊断列表的准确性显著相关.
    结论:由基于AI的症状检查程序开发的鉴别诊断列表的诊断准确性的3年纵向调查,已在现实世界的临床实践中实施,随着时间的推移没有改善。罕见疾病和非典型表现与较低的诊断准确性独立相关。在未来,应该训练症状检查人员来识别不常见的情况。
    BACKGROUND: Artificial intelligence (AI) symptom checker models should be trained using real-world patient data to improve their diagnostic accuracy. Given that AI-based symptom checkers are currently used in clinical practice, their performance should improve over time. However, longitudinal evaluations of the diagnostic accuracy of these symptom checkers are limited.
    OBJECTIVE: This study aimed to assess the longitudinal changes in the accuracy of differential diagnosis lists created by an AI-based symptom checker used in the real world.
    METHODS: This was a single-center, retrospective, observational study. Patients who visited an outpatient clinic without an appointment between May 1, 2019, and April 30, 2022, and who were admitted to a community hospital in Japan within 30 days of their index visit were considered eligible. We only included patients who underwent an AI-based symptom checkup at the index visit, and the diagnosis was finally confirmed during follow-up. Final diagnoses were categorized as common or uncommon, and all cases were categorized as typical or atypical. The primary outcome measure was the accuracy of the differential diagnosis list created by the AI-based symptom checker, defined as the final diagnosis in a list of 10 differential diagnoses created by the symptom checker. To assess the change in the symptom checker\'s diagnostic accuracy over 3 years, we used a chi-square test to compare the primary outcome over 3 periods: from May 1, 2019, to April 30, 2020 (first year); from May 1, 2020, to April 30, 2021 (second year); and from May 1, 2021, to April 30, 2022 (third year).
    RESULTS: A total of 381 patients were included. Common diseases comprised 257 (67.5%) cases, and typical presentations were observed in 298 (78.2%) cases. Overall, the accuracy of the differential diagnosis list created by the AI-based symptom checker was 172 (45.1%), which did not differ across the 3 years (first year: 97/219, 44.3%; second year: 32/72, 44.4%; and third year: 43/90, 47.7%; P=.85). The accuracy of the differential diagnosis list created by the symptom checker was low in those with uncommon diseases (30/124, 24.2%) and atypical presentations (12/83, 14.5%). In the multivariate logistic regression model, common disease (P<.001; odds ratio 4.13, 95% CI 2.50-6.98) and typical presentation (P<.001; odds ratio 6.92, 95% CI 3.62-14.2) were significantly associated with the accuracy of the differential diagnosis list created by the symptom checker.
    CONCLUSIONS: A 3-year longitudinal survey of the diagnostic accuracy of differential diagnosis lists developed by an AI-based symptom checker, which has been implemented in real-world clinical practice settings, showed no improvement over time. Uncommon diseases and atypical presentations were independently associated with a lower diagnostic accuracy. In the future, symptom checkers should be trained to recognize uncommon conditions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    脑膜瘤是一种由蛛网膜细胞引起的轴外肿瘤,通常是良性和缓慢生长的。原发性硬膜外脑膜瘤是指在硬膜下室之外出现的脑膜瘤,极为罕见(占脑膜瘤的0.3%)。
    方法:一名42岁的女性出现在她的初级卫生保健提供者面前,她有2年的左额头疼痛性肿块病史,并有11个月大的机动车事故导致的创伤性脑损伤和颅内血肿病史。超声报告皮脂腺囊肿可能。切除病灶送病理检查。诊断摘要报告了WHO1级异位左额脑膜瘤。
    颅外脑膜瘤分为两类:原发性颅外脑膜瘤和继发性颅外脑膜瘤。在女性人群中,头皮/皮肤上发现的颅外脑膜瘤中有88%是1级脑膜瘤。大多数颅外脑膜瘤是在组织学检查后诊断的,由于稀有。它们可以通过胚胎发育过程中蛛网膜细胞的截留以及由取代蛛网膜细胞的创伤性事件而产生。
    结论:作者认为患者PEM的病因是由于婴儿期创伤性脑损伤继发的蛛网膜胰岛细胞的截留。有趣的是,患者的症状开始于创伤后40年。这种罕见肿瘤的其他病例研究表明,创伤和诊断之间的时间较短。我们建议所有患者都应进行头皮肿块的影像学和组织学检查。
    UNASSIGNED: Meningiomas are an extra-axial tumour arising from arachnoid cells and are typically benign and slow growing. Primary extradural meningiomas refer to meningiomas that arise outside the subdural compartment and are extremely rare (0.3 % of meningiomas).
    METHODS: A 42-year-old female presented to her primary health care provider with a 2-year history of a painful mass on her left forehead with a past medical history of a traumatic brain injury and intracranial hematoma from a motor vehicle accident when she was 11 months old. An ultrasound reported as likely sebaceous cyst. The lesion was resected and sent for pathological examination. The diagnostic summary reported an ectopic subgaleal left frontal meningioma WHO Grade 1.
    UNASSIGNED: Extracranial meningiomas have been divided into two classifications; primary extracranial meningiomas and secondary extracranial meningiomas. In the female population group 88 % of extracranial meningiomas found on the scalp/skin are grade 1 meningiomas. Most extracranial meningiomas are diagnosed after histology examination, due to the rarity. They can arise via entrapment of arachnoid cells during embryologic development and from traumatic events displacing arachnoid cells.
    CONCLUSIONS: The authors suggest that the patient\'s aetiology of her PEM is from the entrapment of arachnoid islet cells secondary to her traumatic brain injury during infancy. Interestingly, the patients\' symptoms began 40 years post trauma. Other case studies of this rare tumour have correlated a shorter time period between the trauma and the diagnosis. We suggest that all patients should have radiographic and histologic investigations of scalp masses.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    罕见的癌症是那些一年中发病率低于6/100,000的癌症。平均而言,罕见癌症患者的5年相对生存率比普通癌症患者差.由于临床证据有限和缺乏知情决策的经验证据,罕见癌症患者的癌症创伤经历可能会进一步加剧。罕见癌症累计占所有癌症的25%,加上全球社会罕见癌症的负担不断上升,有必要确定罕见癌症患者的心理结局。
    这篇PRISMA坚持的系统综述(PROSPERO:CRD42023475748)涉及对PubMed的系统搜索,Embase,Cochrane和PsycINFO自2000年至2024年1月30日发表的所有同行评审的英语语言研究,评估了患病率,抑郁症的发病率和风险,焦虑,自杀,和罕见癌症患者的创伤后应激障碍(PTSD)。两名独立审稿人从已发表的研究中评估并提取了摘要数据。随机效应荟萃分析和荟萃回归用于主要分析。
    我们纳入了32项研究,涉及57,470例罕见癌症患者。荟萃分析表明,与健康对照组相比,罕见癌症患者的抑郁(RR=2.61,95%CI:1.43-4.77,I2=97%)和焦虑(RR=2.66,95%CI:1.27-5.55,I2=92%)的风险比(RR)显着增加。我们确定了高自杀率(每10万人年有315人,95%CI:162-609,I2=95%),抑郁症患病率(17%,95%CI:14-22,I2=88%),焦虑(20%,95%CI:15-25,I2=96%)和创伤后应激障碍(18%,95%CI:9-32,I2=25%)。与常见癌症类型的患者相比,自杀发生率,罕见癌症患者的PTSD患病率明显更高。系统评价发现,患有晚期疾病,化疗治疗,收入较低,社会地位是负面心理结局的危险因素。
    我们强调需要早期识别罕见癌症患者的心理适应不良。此外,确定有效干预措施的研究势在必行。
    这项研究得到了国家医学研究委员会过渡奖的支持,SingHealthDuke-NUS肿瘤学学术临床计划,Khoo飞行员合作奖,国家医学研究委员会临床科学家-个人研究资助-新研究者资助,特里·福克斯·格兰特和KhooBridge基金奖。
    UNASSIGNED: Rare cancers are those that exhibit an incidence of less than six per 100,000 in a year. On average, the five-year relative survival for patients with rare cancers is worse than those with common cancers. The traumatic experience of cancer can be further intensified in patients with rare cancers due to the limited clinical evidence and the lack of empirical evidence for informed decision-making. With rare cancers cumulatively accounting for up to 25% of all cancers, coupled with the rising burden of rare cancers on societies globally, it is necessary to determine the psychological outcomes of patients with rare cancers.
    UNASSIGNED: This PRISMA-adherent systematic review (PROSPERO: CRD42023475748) involved a systematic search of PubMed, Embase, Cochrane and PsycINFO for all peer-reviewed English language studies published since 2000 to 30th January 2024 that evaluated the prevalence, incidence and risk of depression, anxiety, suicide, and post-traumatic stress disorder (PTSD) in patients with rare cancers. Two independent reviewers appraised and extracted the summary data from published studies. Random effects meta-analyses and meta-regression were used for primary analysis.
    UNASSIGNED: We included 32 studies with 57,470 patients with rare cancers. Meta-analyses indicated a statistically significant increased risk-ratio (RR) of depression (RR = 2.61, 95% CI: 1.43-4.77, I2 = 97%) and anxiety (RR = 2.66, 95% CI: 1.27-5.55, I2 = 92%) in patients with rare cancers compared to healthy controls. We identified a high suicide incidence (315 per 100,000 person-years, 95% CI: 162-609, I2 = 95%), prevalence of depression (17%, 95% CI: 14-22, I2 = 88%), anxiety (20%, 95% CI: 15-25, I2 = 96%) and PTSD (18%, 95% CI: 9-32, I2 = 25%). When compared to patients with common cancer types, suicide incidence, and PTSD prevalence were significantly higher in patients with rare cancers. Systematic review found that having advanced disease, chemotherapy treatment, lower income, and social status were risk factors for negative psychological outcomes.
    UNASSIGNED: We highlight the need for early identification of psychological maladjustment in patients with rare cancers. Additionally, studies to identify effective interventions are imperative.
    UNASSIGNED: This study was supported by the National Medical Research Council Transition Award, SingHealth Duke-NUS Oncology Academic Clinical Programme, the Khoo Pilot Collaborative Award, the National Medical Research Council Clinician Scientist-Individual Research Grant-New Investigator Grant, the Terry Fox Grant and the Khoo Bridge Funding Award.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在一个充满成本压力的时代,替代仿制药是医疗保健系统的主要成本控制策略之一。尽管有明显的经济利益,在少数情况下,替代可能需要谨慎甚至禁忌。在大多数司法管辖区,为了获得批准,具有品牌等同物的通用产品的生物等效性需要通过健康受试者的生物利用度研究来证明。罕见疾病,定义为低患病率的医疗条件,是一组通常很严重的异质性疾病,禁用,进步,退化,危及生命或长期衰弱,不成比例地影响年轻人和老年人。尽管罕见疾病有这些独特的特征,一般生物等效性研究通常以单剂量进行,排除儿童或老年人.此外,仿制药/生物仿制药产品的辅料和生产工艺可能与品牌产品不同,这可能会影响产品的保质期,它的外观,气味,味道,生物利用度,安全性和效力。这可能导致批准在其目标人群中不具有生物等效性/可比性或符合生物等效性但不符合治疗等效性标准的仿制药/生物仿制药。另一个问题涉及由于生物蠕变现象而无法保证的仿制药和生物仿制药的互换性。这篇综述总结了孤儿药的通用替代的潜在问题,并讨论了潜在的问题病例,包括狭窄的治疗指数药物或治疗失败可能导致严重并发症甚至死亡的关键条件。最后,我们提出需要完善监管框架,重点是沙特阿拉伯,通用替代和最近朝着这个方向的努力。
    In an era of cost pressure, substituting generic drugs represents one of the main cost-containment strategies of healthcare systems. Despite the obvious financial benefits, in a minority of cases, substitution may require caution or even be contraindicated. In most jurisdictions, to obtain approval, the bioequivalence of generic products with the brand-name equivalent needs to be shown via bioavailability studies in healthy subjects. Rare diseases, defined as medical conditions with a low prevalence, are a group of heterogenous diseases that are typically severe, disabling, progressive, degenerative, and life-threatening or chronically debilitating, and disproportionally affect the very young and elderly. Despite these unique features of rare diseases, generic bioequivalence studies are typically carried out with single doses and exclude children or the elderly. Furthermore, the excipients and manufacturing processes for generic/biosimilar products can differ from the brand products which may affect the shelf-life of the product, its appearance, smell, taste, bioavailability, safety and potency. This may result in approval of generics/biosimilars which are not bioequivalent/comparable in their target population or that meet bioequivalence but not therapeutic equivalence criteria. Another concern relates to the interchangeability of generics and biosimilars which cannot be guaranteed due to the phenomenon of biocreep. This review summarizes potential concerns with generic substitution of orphan drugs and discusses potentially problematic cases including narrow therapeutic index drugs or critical conditions where therapeutic failure could lead to serious complications or even death. Finally, we put forward the need for refining regulatory frameworks, with emphasis on Saudi Arabia, for generic substitution and recent efforts toward this direction.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    后交叉韧带(PCL)的眼泪很少见,后交叉韧带胫骨连接部的撕脱性骨折更为罕见。这些伤害通常发生在车祸等事故中,引起急性疼痛,肿胀以及膝关节完全功能性阳痿。对这些损伤发生率的研究显示出不同的结果,但是似乎有上升的趋势。PCL撕脱骨折的手术治疗尚不明确,尽管关节镜技术由于其潜在的益处而变得越来越流行。然而,一些医疗中心可能有限地使用这些方法,因此更喜欢开放手术选择。报告一例36岁女性患者的LCP撕脱性骨折,手术成功进行,六个月后完全恢复,膝盖活动能力和后部稳定。
    Tears of the posterior cruciate ligament (PCL) are rare, and avulsion fracture of the tibial attachment of the posterior cruciate ligament is even rarer. These injuries usually occur in accidents such as car crashes, causing acute pain, swelling as well as total functional impotence of the knee. Studies on the incidence of these injuries show variable results, but there appears to be an upward trend. The surgical management of PCL avulsion fracture is not clearly established, although arthroscopic techniques are becoming more popular due to their potential benefits. However, some medical centers may have limited access to these methods, thus preferring open surgery options. A case of LCP avulsion fracture in a 36-year-old female patient was reported, and surgery was successfully performed, leading to full recovery after six months with full knee mobility and posterior stability.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    局限性硬皮病是一种结缔组织疾病,可导致过多的胶原蛋白沉积和皮肤纤维化。它可以细分为硬皮病和线性硬皮病。Encoupdesabre(ECDS)是一种罕见的线性硬皮病,通常在儿童中发现。除了叶酸补充剂外,通常还使用甲氨蝶呤和皮质疗法进行治疗。迄今为止,据报道,很少有口腔受累的ECDS病例.此病例报告讨论了一名患有线性硬皮病ECDS的7岁女孩,她被转诊到牙科诊所评估口腔底部的肌肉肥大。在临床和影像学检查中,病人的舌骨肌萎缩,患侧牙槽骨高度降低,以及受影响一侧的中线偏离。此外,患者被归类为患龋风险高.在与主治医生就治疗方式和选择进行协商后,患者在利雅得费萨尔国王专科医院和研究中心的牙科部门完成了全面的牙科治疗,沙特阿拉伯。
    Localized scleroderma is a connective tissue disorder that causes excessive collagen deposition and skin fibrosis. It can be subdivided into morphea and linear scleroderma. En coup de sabre (ECDS) is a rare variant of linear scleroderma typically found among children. It is usually treated with methotrexate and corticotherapy in addition to folic acid supplements. To date, few cases of ECDS have been reported with oral involvement. This case report discusses a seven-year-old girl with linear scleroderma ECDS who was referred to the dental clinic to evaluate muscular hypotrophy on the floor of the mouth. Upon clinical and radiographic examination, the patient had hypotrophied mylohyoid muscle, reduced alveolar bone height on the affected side, and a deviated midline to the affected side as well. Furthermore, the patient was classified as having a high caries risk. After consultation with the primary physician regarding treatment modalities and options, the patient completed her comprehensive dental treatment at the Dental Department at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    Takayasu动脉炎(TAK)是一种病因不明的罕见大血管血管炎,可导致动脉壁增厚,狭窄,和遮挡,这可能使脑血管缺血事件复杂化。缺血性卒中是TAK年轻时的潜在毁灭性并发症,但这种情况在埃塞俄比亚仍然很少报道。虽然它发生在病情的后期,这可能是最初的表现,提示预后不良.在这里,我们处理了一个25岁的妇女,她在中风2年后随访期间到大学医院就诊,临床症状恶化,肱动脉搏动缺失,和双臂无法记录的血压。在2021年入院时,对比脑计算机断层扫描显示右侧大脑中动脉区域缺血性梗塞。然而,由于临床表现的模糊性和临床医生无法将TAK纳入鉴别诊断,当时无法确定中风的病因,导致病例的早期诊断延迟。两年后,2023年,她接受了计算机断层扫描血管造影,并根据美国风湿病学会的标准被诊断出患有TAK,NumanoIIb型血管造影疾病范围,缺血性卒中,和II期全身性高血压。该患者由专家治疗。该病例强调,在没有传统危险因素的情况下,年轻患者中风的鉴别诊断需要考虑TAK;应进行适当的检查以确认或排除这种诊断。和管理应该相应地修改。
    Takayasu arteritis (TAK) is a rare large-vessel vasculitis of unknown etiology that leads to arterial wall thickening, stenosis, and occlusion, which may complicate cerebrovascular ischemic events. Ischemic stroke is a potentially devastating complication of TAK at a young age, but the occurrence is still rarely reported in Ethiopia. Although it occurs late in the course of the condition, it may be the initial presentation and suggest an unfavorable prognosis. Herein, we address the case of a 25-year-old woman who presented to a university hospital while on follow-up after 2 years of stroke with deterioration in clinical symptoms, absent brachial artery pulses, and unrecordable blood pressure in both arms. At the time of admission in 2021, the contrast brain computed tomography scan revealed an ischemic infarction in the right middle cerebral artery territory. However, the etiology of the stroke could not be defined at that time due to ambiguity in the clinical picture and the inability of clinicians to incorporate TAK into the differential diagnosis, resulting in a delay in the early diagnosis of the case. Two years later, in 2023, she underwent computed tomography angiography and was diagnosed to have TAK based on American College of Rheumatology criteria, with Numano type IIb angiographic extent of disease, ischemic stroke, and stage II systemic hypertension. The patient was treated by a field of experts. This case highlights the need to consider TAK in the differential diagnosis of stroke in young patients in the absence of traditional risk factors; appropriate tests should be performed to confirm or rule out this diagnosis, and management should be modified accordingly.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号